ArticleFrontiers in cellular and infection microbiology2025
Clinical characteristics, risk factors and prognosis of
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- AcuteThe Journal of international medical research · 2026Article
- Emergence of gene associations in high-risk K. pneumoniae clones: blaArchives of microbiology · 2026Article
- Analysis of risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infections in children: a case-control study.BMC microbiology · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Risk factors, resistance profiles, and clinical outcomes ofFrontiers in cellular and infection microbiology · 2026Article
- Genome Sequencing and Comparative Genomic Analysis of Multidrug-ResistantInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of our study was to investigate the epidemiology and risk factors of Methods: We conducted a retrospective study in immunocompromised and immunocompetent patients with KP infections who were admitted to Chaohu Hospital of Anhui Medical University from January 2023 to December 2023. We compared demographics, clinical characteristics, treatments, and outcomes across these groups and examined the impact of ESBL-KP, CRKP and non-MDR-KP on cumulative survival rates in populations with different immune states by plotting Kaplan-Meier curves. Results: Our study included 228 immunocompromised patients and 200 immunocompetent patients. Compared to the immunocompetent group, immunocompromised patients were more likely to have a history of surgery and to use hormone frequently. They tended to rely more on medical devices, including urinary catheters, nasogastric catheters, arterial catheters, venous catheters, mechanical ventilation and endoscopy. Immunocompromised patients had a poorer recovery and were rehospitalized more often than those in immunocompetent patients. In the multivariable analysis, age-adjusted Charlson comorbidity index (aCCI) (OR: 1.292, 95%CI: 1.086-1.537, Conclusion: The clinical characteristics, treatment process and prognosis in immunocompromised patients with KP infections are significantly different from those in immunocompetent patients. In clinical settings, the standardization of invasive procedures and the rational use of antibiotics represent the most effective strategies for preventing and treating KP infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.